Pinned post
Great to have our work on immune response after extended dosing interval for Pfizer BNT162b2 now formally out in peer review in Cell. Here's a 🧵from 1 of the paper's 1st authors outlining the paper. Great teamwork from the many involved - see end of thread for collaborators 👋
1/ Proud to be part of this @pitchstudy ‘Immunogenicity of standard and extended dosing intervals of @pfizer BNT162b2 mRNA vaccine’ which is out in @CellCellPress cell.com/cell/fulltext/…View quoted post on X
Thread below 👇